Gilead Discontinuing Development of Magrolimab in Hematologic Cancers Following Full Clinical Hold by FDA for Increased Risk of Death

Data from the ENHANCE-3 trial of magrolimab in combination with azacitidine plus Venclexta showed futility and an increased risk of death in patients with acute myeloid leukemia.

Source link
#Gilead #Discontinuing #Development #Magrolimab #Hematologic #Cancers #Full #Clinical #Hold #FDA #Increased #Risk #Death